vs
Side-by-side financial comparison of CHAMPIONS ONCOLOGY, INC. (CSBR) and Recon Technology, Ltd (RCON). Click either name above to swap in a different company.
CHAMPIONS ONCOLOGY, INC. is the larger business by last-quarter revenue ($15.0M vs $12.2M, roughly 1.2× Recon Technology, Ltd). CHAMPIONS ONCOLOGY, INC. runs the higher net margin — 1.8% vs -6.8%, a 8.6% gap on every dollar of revenue. On growth, Recon Technology, Ltd posted the faster year-over-year revenue change (111.0% vs 11.5%).
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
Recon Instruments Inc. was a Canadian technology company that produced smartglasses and wearable displays marketed by the company as "heads-up displays" for sports. Recon's products delivered live activity metrics, GPS maps, and notifications directly to the user's eye. Recon's first heads-up display offering was released commercially in October 2010, roughly a year and a half before Google introduced Google Glass.
CSBR vs RCON — Head-to-Head
Income Statement — Q2 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $12.2M |
| Net Profit | $268.0K | $-832.7K |
| Gross Margin | 51.7% | 33.5% |
| Operating Margin | 1.2% | -14.6% |
| Net Margin | 1.8% | -6.8% |
| Revenue YoY | 11.5% | 111.0% |
| Net Profit YoY | -63.2% | 70.5% |
| EPS (diluted) | $0.02 | $-0.09 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.0M | $12.2M | ||
| Q3 25 | $14.0M | — | ||
| Q2 25 | $12.4M | — | ||
| Q1 25 | $17.0M | — | ||
| Q4 24 | $13.5M | $5.8M | ||
| Q3 24 | $14.1M | — | ||
| Q2 24 | $14.0M | — | ||
| Q1 24 | $12.0M | — |
| Q4 25 | $268.0K | $-832.7K | ||
| Q3 25 | $-436.0K | — | ||
| Q2 25 | $-1.8M | — | ||
| Q1 25 | $4.5M | — | ||
| Q4 24 | $728.0K | $-2.8M | ||
| Q3 24 | $1.3M | — | ||
| Q2 24 | $-109.0K | — | ||
| Q1 24 | $-2.5M | — |
| Q4 25 | 51.7% | 33.5% | ||
| Q3 25 | 42.9% | — | ||
| Q2 25 | 41.1% | — | ||
| Q1 25 | 61.2% | — | ||
| Q4 24 | 44.9% | 31.7% | ||
| Q3 24 | 49.7% | — | ||
| Q2 24 | 48.2% | — | ||
| Q1 24 | 34.7% | — |
| Q4 25 | 1.2% | -14.6% | ||
| Q3 25 | -3.8% | — | ||
| Q2 25 | -16.2% | — | ||
| Q1 25 | 26.4% | — | ||
| Q4 24 | 5.4% | -63.9% | ||
| Q3 24 | 9.5% | — | ||
| Q2 24 | -1.9% | — | ||
| Q1 24 | -21.4% | — |
| Q4 25 | 1.8% | -6.8% | ||
| Q3 25 | -3.1% | — | ||
| Q2 25 | -14.9% | — | ||
| Q1 25 | 26.4% | — | ||
| Q4 24 | 5.4% | -48.9% | ||
| Q3 24 | 9.3% | — | ||
| Q2 24 | -0.8% | — | ||
| Q1 24 | -21.1% | — |
| Q4 25 | $0.02 | $-0.09 | ||
| Q3 25 | $-0.03 | — | ||
| Q2 25 | $-0.12 | — | ||
| Q1 25 | $0.31 | — | ||
| Q4 24 | $0.05 | $-0.31 | ||
| Q3 24 | $0.09 | — | ||
| Q2 24 | $-0.01 | — | ||
| Q1 24 | $-0.19 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | $10.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.2M | $66.4M |
| Total Assets | $30.2M | $77.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | $10.7M | ||
| Q3 25 | $10.3M | — | ||
| Q2 25 | $9.8M | — | ||
| Q1 25 | $3.2M | — | ||
| Q4 24 | $2.8M | $19.9M | ||
| Q3 24 | $2.9M | — | ||
| Q2 24 | $2.6M | — | ||
| Q1 24 | $4.5M | — |
| Q4 25 | $4.2M | $66.4M | ||
| Q3 25 | $3.5M | — | ||
| Q2 25 | $3.8M | — | ||
| Q1 25 | $5.5M | — | ||
| Q4 24 | $681.0K | $66.9M | ||
| Q3 24 | $-332.0K | — | ||
| Q2 24 | $-1.9M | — | ||
| Q1 24 | $-2.1M | — |
| Q4 25 | $30.2M | $77.6M | ||
| Q3 25 | $30.5M | — | ||
| Q2 25 | $32.3M | — | ||
| Q1 25 | $30.6M | — | ||
| Q4 24 | $25.2M | $74.2M | ||
| Q3 24 | $24.9M | — | ||
| Q2 24 | $26.1M | — | ||
| Q1 24 | $26.8M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $-1.9M |
| Free Cash FlowOCF − Capex | $-2.0M | — |
| FCF MarginFCF / Revenue | -13.1% | — |
| Capex IntensityCapex / Revenue | 1.6% | — |
| Cash ConversionOCF / Net Profit | -6.47× | — |
| TTM Free Cash FlowTrailing 4 quarters | $5.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.7M | $-1.9M | ||
| Q3 25 | $600.0K | — | ||
| Q2 25 | $6.9M | — | ||
| Q1 25 | $490.0K | — | ||
| Q4 24 | $-283.0K | $-1.7M | ||
| Q3 24 | $311.0K | — | ||
| Q2 24 | $-1.8M | — | ||
| Q1 24 | $-919.0K | — |
| Q4 25 | $-2.0M | — | ||
| Q3 25 | $554.0K | — | ||
| Q2 25 | $6.6M | — | ||
| Q1 25 | $448.0K | — | ||
| Q4 24 | $-377.0K | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-1.8M | — | ||
| Q1 24 | $-1.0M | — |
| Q4 25 | -13.1% | — | ||
| Q3 25 | 4.0% | — | ||
| Q2 25 | 53.5% | — | ||
| Q1 25 | 2.6% | — | ||
| Q4 24 | -2.8% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -13.0% | — | ||
| Q1 24 | -8.4% | — |
| Q4 25 | 1.6% | — | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.7% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.8% | — |
| Q4 25 | -6.47× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.11× | — | ||
| Q4 24 | -0.39× | — | ||
| Q3 24 | 0.24× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
RCON
Segment breakdown not available.
